Biopharmaceutical companies that get stuck with legacy technologies, including older stainless steel equipment, and older processes, end up watching as competitors transition to more efficient, cost-effective platforms. But this isn’t just a cost-of-production issue; it goes to more strategic factors like being able to even participate in the emerging biosimilars markets, as well as being able to participate in global emerging economies.
Our 11thAnnual Report of Biopharmace...
